HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice

Cancer Research

Volumn 60, Issue 23, 2000, Pages 6737-6743

  Kuba, K ^a   Matsumoto, K ^a   Date, K ^a   Shimura, H ^a   Tanaka, M ^a   Nakamura, T ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; NK4; SCATTER FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CHORIOALLANTOIS; CORNEA NEOVASCULARIZATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; KRINGLE DOMAIN; LEWIS CARCINOMA; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ALLANTOIS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; CHICK EMBRYO; CHO CELLS; CHORION; CRICETINAE; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; GROWTH INHIBITORS; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MET; RABBITS; RECOMBINANT PROTEINS; TYROSINE;

EID: 0034547912     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats
2. Molecular cloning and expression of human hepatocyte growth factor
3. The many faces of hepatocyte growth factor: From hepatopoiesis to hematopoiesis
4. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration
5. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase
6. The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis
7. Scatter factor and angiogenesis
8. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis
9. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers
10. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer
11. Regulation of fibroblast hepatocyte growth factor/scatter factor expression by human breast carcinoma cell lines and peptide growth factors
12. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions
13. Met expression and sarcoma tumorigenicity
14. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas
15. Activating mutations for the met tyrosine kinase receptor in human cancer
16. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists
17. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor
18. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor
19. Identification of a competitive HGF antagonist encoded by an alternative transcript
20. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis
21. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity
22. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo
23. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
24. Mechanisms of angiogenesis
25. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
26. Tumor angiogenesis: The role of oncogenes and tumor suppressor genes
27. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides
28. Requirement of vascular integrin αvβ3 for angiogenesis
29. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
30. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
31. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
32. Thalidomide is an inhibitor of angiogenesis
33. Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocytes
34. Multiple forms of angiostatin induce apoptosis in endothelial cells
35. Analysis of rejection mechanism in the rat to mouse cardiac xenotransplantation. Role and characteristics of anti-endothelial cell antibodies
36. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
37. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
38. Inhibitory effects of anti-angiogenic agents on neovascularization and growth of the chorioallantoic membrane (CAM). The possibility of a new CAM assay for angiogenesis inhibition
39. Tumor growth and neovascularization: An experimental model using the rabbit cornea
40. Assay and purification of naturally occurring inhibitor of angiogenesis
41. Angiostatin induces and sustains dormancy of human primary tumors in mice
42. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells
43. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells
44. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth
45. Prothrombin kringle-2 domain has a growth inhibitory activity against basic fibroblast growth factor-stimulated capillary endothelial cells
46. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
47. Critical factors in the biology of human cancer metastasis: Twenty-eighth G. H. A. Clowes memorial award lecture
48. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation
49. Intratumor microvessel density as a prognostic factor in cancer
50. Scatter factor: Molecular characteristics and effect on the invasiveness of epithelial cells
51. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells
52. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network
53. Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells
54. Halting angiogenesis suppresses carcinoma cell invasion
55. Reversion of human glioblastoma malignancy by U small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression
56. A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth
57. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network